Literature DB >> 3830243

Kinetics of cotinine after oral and intravenous administration to man.

P J De Schepper, A Van Hecken, P Daenens, J M Van Rossum.   

Abstract

Cotinine, the main metabolite of nicotine, was administered intravenously to healthy male non-smoking volunteers in doses of 5, 10 and 20 mg, and orally in doses of 10 and 20 mg. Intravenous administration was characterized by a dose-independent half-life of 12.2 h, mean residence time of 15.9 h, total clearance of 3.64 l h-1 and a volume of distribution of 56.5 l. Renal clearance was 0.46 l h-1 and approximately 12.0% of the dose was excreted unchanged in the urine. The mean absorption time after oral dosing ranged between 1 and 3 h, the peak concentration was reached within 45 min and the mean elimination half-lives were 12.9 and 11.7 h, respectively, after the 10 and 20 mg doses. Systemic bioavailability ranged between 0.84 and 1.11 following 10 mg and between 0.97 and 1.03 following the 20 mg dose. Mean urinary recovery and renal clearance were almost identical with the values after iv administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3830243     DOI: 10.1007/bf00606635

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Metabolism of nicotine in the human and excretion of pyridine compounds by smokers.

Authors:  E R BOWMAN; L B TURNBULL; H McKENNIS
Journal:  J Pharmacol Exp Ther       Date:  1959-10       Impact factor: 4.030

2.  Cotinine excretion and daily cigarette smoking in habituated smokers.

Authors:  S Matsukura; N Sakamoto; Y Seino; T Tamada; H Matsuyama; H Muranaka
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

3.  Verification of smoking history in patients after infarction using urinary nicotine and cotinine measurements.

Authors:  R G Wilcox; J Hughes; J Roland
Journal:  Br Med J       Date:  1979-10-27

4.  Smoker intake from cigarettes in the 1-mg Federal Trade Commission tar class.

Authors:  G B Gori; C J Lynch
Journal:  Regul Toxicol Pharmacol       Date:  1983-06       Impact factor: 3.271

5.  Determination of cotinine in biological fluids by capillary gas chromatography-mass spectrometry-selected-ion monitoring.

Authors:  P Daenens; L Laruelle; K Callewaert; P De Schepper; R Galeazzi; J van Rossum
Journal:  J Chromatogr       Date:  1985-07-12

Review 6.  Biosynthesis and mammalian metabolism of nicotine.

Authors:  A Pilotti
Journal:  Acta Physiol Scand Suppl       Date:  1980

7.  Disposition kinetics and effects of intravenous nicotine.

Authors:  J Rosenberg; N L Benowitz; P Jacob; K M Wilson
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

8.  Steady-state concentration of cotinine as a measure of nicotine-intake by smokers.

Authors:  R L Galeazzi; P Daenens; M Gugger
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Cotinine disposition and effects.

Authors:  N L Benowitz; F Kuyt; P Jacob; R T Jones; A L Osman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

10.  Smokers of low-yield cigarettes do not consume less nicotine.

Authors:  N L Benowitz; S M Hall; R I Herning; P Jacob; R T Jones; A L Osman
Journal:  N Engl J Med       Date:  1983-07-21       Impact factor: 91.245

View more
  11 in total

1.  Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function.

Authors:  Pei Li; Wayne D Beck; Patrick M Callahan; Alvin V Terry; Michael G Bartlett
Journal:  Pharmacol Rep       Date:  2014-12-16       Impact factor: 3.024

2.  The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.

Authors:  M Curvall; C E Elwin; E Kazemi-Vala; C Warholm; C R Enzell
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetics from a dynamical systems point of view.

Authors:  J M van Rossum; J E de Bie; G van Lingen; H W Teeuwen
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

4.  A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites.

Authors:  F K St Charles; G R Krautter; M Dixon; D C Mariner
Journal:  Psychopharmacology (Berl)       Date:  2006-10-07       Impact factor: 4.530

5.  A physiologically based pharmacokinetic model for nicotine and cotinine in man.

Authors:  D E Robinson; N J Balter; S L Schwartz
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

6.  Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat.

Authors:  J Gabrielsson; U Bondesson
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

Review 7.  New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine.

Authors:  J Alex Grizzell; Valentina Echeverria
Journal:  Neurochem Res       Date:  2014-06-27       Impact factor: 3.996

8.  Comprehensive Parent-Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies.

Authors:  Lukas Kovar; Dominik Selzer; Hannah Britz; Neal Benowitz; Gideon St Helen; Yvonne Kohl; Robert Bals; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2020-09       Impact factor: 6.447

9.  Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.

Authors:  Valentina Echeverria Moran
Journal:  Front Pharmacol       Date:  2012-10-10       Impact factor: 5.810

10.  Acute changes in atherogenic and thrombogenic factors with cessation of smoking.

Authors:  M D Feher; M W Rampling; J Brown; R Robinson; W Richmond; S Cholerton; B J Bain; P S Sever
Journal:  J R Soc Med       Date:  1990-03       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.